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Background & aims: Elevated soluble HLA-DR (sHLA-DR) serum levels have been reported in HLA class II-
associated inflammatory disorders. We have previously shown that the HLA class II allele HLA-DRB1*01
may predispose to acute coronary syndromes (ACS). To our knowledge, sHLA-DR serum levels have not
been studied in ACS.
Methods: sHLA-DR serum levels were measured in 477 ACS patients as cases and 475 area- and sex-
matched controls by sandwich enzyme-linked immunosorbent assay. Binary logistic regression and
ordinal logistic regression analyses adjusted for clinical parameters were conducted to evaluate the
associations of sHLA-DR levels.
Results: ACS patients had lower sHLA-DR serum levels compared to controls (OR ¼ 0.837; 95% CI ¼ 0.704
e0.994; p ¼ 0.043). After adjustment for smoking status, this association was no longer significant. This
was explained by the notion that current smoking was inversely associated with sHLA-DR levels both in
cases (OR ¼ 0.592; 95% CI ¼ 0.553e0.908; p ¼ 0.016) and in controls (OR ¼ 0.356; 95% CI ¼ 0.226e0.563;
p ¼ 0.000010). A similar effect was not seen with other cardiovascular risk factors.
Conclusions: The results indicate, for the first time, that lower sHLA-DR levels are associated with
smoking, but not with ACS. This is an important finding because previous studies of sHLA-DR have not
accounted for the possible associations between smoking and sHLA-DR levels. Further studies are
required to confirm these novel results and explore the mechanisms behind the observed associations.
© 2017 Elsevier B.V. All rights reserved.1. Introduction
Human leukocyte antigen (HLA)-DR molecules are present on
the cell surface of antigen-presenting cells and can trigger immune
reactions by presenting antigens to CD4 positive T-lymphocytes.
HLA-DR molecules are also found in a soluble form (sHLA-DR) in
almost every human body fluid including saliva, sweat, tears,
serum, synovial fluid and urine [1e3]. sHLA-DR correlates with the
amount of expression of membrane bound HLA-DR, possibly
reflecting the inflammatory status [4].ory, University of Helsinki,
lva).According to previous studies, sHLA-DR serum or plasma levels
have been reported to be elevated in patients with inflammatory
diseases such as acute phase of multiple sclerosis [5], rheumatoid
arthritis [6] and autoimmune hepatitis [7]. In patients with rheu-
matoid arthritis, sHLA-DR serum levels also correlated with disease
activity [8] and decreased after immunosuppressive therapy with
cyclosporine A [9]. On the other hand, decreased sHLA-DR serum
levels have been associated with end-stage heart disease [10] and
severe sepsis [11], and in patients with melanoma, sHLA-DR serum
levels declined as the cancer progressed [12].
Disorders showing increased sHLA-DR serum levels havemostly
been reported to be HLA class II-associated inflammatory disorders.
HLA-DR-positive lymphocytes have been associated with acute
coronary syndrome (ACS) [13] and we have shown that the HLA
class II allele HLA-DRB1*01 may predispose to ACS [14,15]. In this
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levels, ACS and cardiovascular risk factors.
2. Materials and methods
2.1. Study subjects
We selected ACS patients from the COROGENE study cohort of
5000 patients undergoing coronary angiogram at the Helsinki
University Hospital in Finland between June 2006 and March 2008
[16]. Inclusion criteria in the current studywere i) ACS, ii) age under
55 years for men and under 65 years for women, iii) home address
in the capital region in Finland, yielding 488 cases in total. After
excluding the cases withmissing serum samples, the group of cases
consisted of 477 ACS patients.
475 study subjects from the FINRISK 2007 study cohort served
as sex- and area-matched controls [17]. The controls had to be free
of cardiovascular disease at baseline. Details of the study subject
selection and baseline measurements are reported in the
Supplementary data.
All the study subjects gave their signed informed consent. The
study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki and the Ethics Committee of the University
of Helsinki approved the COROGENE study and the Coordinating
Ethical Committee of the Helsinki and Uusimaa Hospital District
approved the FINRISK study.
2.2. Quantification of soluble HLA-DR
We detected sHLA-DR serum levels by sandwich enzyme-linked
immunosorbent assay (ELISA) method developed in-house,
described in detail in the Supplementary data.
2.3. HLA-DRB1*01 analyses
HLA-DRB1*01 genotypes from cases and controls were analysed
from genomic DNA by real-time quantitative polymerase chain
reaction technique with sequence specific primers as previously
described [18]. Genotypingwas unsuccessful in 1 case sample and 3
control samples. HLA-DRB1*01 carrier status was considered posi-
tive with 1 or 2 allele copies of HLA-DRB1*01.
2.4. Analyses for other parameters
All laboratory parameters: C-reactive protein (CRP), total
leukocyte count (TLC), total cholesterol (TC), high-density lipo-
protein-cholesterol (HDL-C), low-density lipoprotein-cholesterol
(LDL-C), triglycerides (TG) and troponin T (TnT) were defined ac-
cording to the laboratory standards of HUSLAB (Helsinki University
Hospital Laboratory).
2.5. Statistical analyses
All the statistical calculations were performed with SPSS 21.0
(SPSS Inc., Chicago, IL, USA). We considered results significant at
two-tailed p < 0.05 not correcting for multiple comparisons. sHLA-
DR levels in serum samples were analysed both as a continuous
variable and as a categorical variable as described in detail below.
sHLA-DR levels under the detection limit (<0.1 mg/ml) were
considered as 0.05 mg/ml when analysing the continuous sHLA-DR
variable. sHLA-DR levels and other continuous variables were not
normally distributed by the Kolmogorov-Smirnov normality test
and logarithmic transformation did not transform them as such,
apart from LDL-C and TC levels in controls and HDL-C in cases and
controls. All the continuous variables are expressed asmean ± standard deviation (SD) and categorical variables as count
(percentage). We compared continuous variables with a Mann-
Whitney U test, Kruskal-Wallis test and Jonckheere-Terpstra test
for trend, which are independent of distributional assumptions.
Correlations between clinical parameters and sHLA-DR levels were
analysed by nonparametric Spearman's rank-order correlation test.
Based on the visual inspection of the distribution of the
continuous sHLA-DR-variable, we cathegorized sHLA-DR levels into
four groups: (I) under the detection limit of 0.100 mg/ml, (II)
0.100e0.300 mg/ml, (III) 0.301e2.000 mg/ml and (IV) over 2.000 mg/
ml, to obtain a categorical variable of sHLA-DR levels. A Chi-square
test, a Mantel-Haenszel Linear-by-Linear Association test for trends
or Fisher's exact test was used to determine associations between
categorical variables. We compared cases and controls regarding
logarithmically transformed sHLA-DR levels in binary logistic
regression models, firstly adjusted for age and sex, secondly
adjusted for age, sex and smoking status, thirdly in a multivariable-
adjusted model (adjusted for sex and parameters differing between
cases and controls: age, body mass index [BMI], smoking status,
diabetes, asthma, cancer and CRP), and finally in a multivariable-
adjusted model without smoking status.
We performed ordinal logistic regression models adjusted for
age and sex using categorical sHLA-DR as a dependent variable, and
BMI, smoking status (current versus never-smoking), diabetes,
HLA-DRB1*01, asthma, cancer, rheumatoid arthritis or CRP as
explanatory variables, first separately and then together in the
samemodel, to assess the influences of different cardiovascular risk
factors on the sHLA-DR levels, determining OR and 95% confidence
intervals (95% CIs) for ordinal logistic regressionmodels. This OR for
a specific explanatory variable measures the odds of being in a
group of a higher sHLA-DR level (higher group defined as any of the
three separate ways: group IV vs. groups I-III, groups III and IV vs. I
and II and groups II-IV vs. group I) compared to the groups of lower
sHLA-DR level. Proportional odds of ordinal regression analyses
met the criteria for p > 0.050.
3. Results
3.1. Baseline characteristics
Baseline characteristics are shown in Table 1. As expected, the
cases had more cardiovascular risk factors and cardiovascular
medications. Among cases, the distribution of different ACS types
was the following: unstable angina 8.2% (n ¼ 39), ST elevation
myocardial infarction 47.6% (n ¼ 227) and noneST elevation
myocardial infarction 44.2% (n ¼ 211).
3.2. sHLA-DR levels
Table 2 presents the sHLA-DR serum levels in the study subjects.
Cases had significantly lower levels of sHLA-DR (mean
1.71 ± 9.53 mg/ml) than controls (mean 2.83 ± 17.11 mg/ml;
p ¼ 0.032). The linear trend was borderline insignificant
(p ¼ 0.050), showing lower sHLA-DR levels in cases than controls.
However, sHLA-DR levels over the 95th percentile (>6.67 mg/ml) of
the control group were found with a similar frequency in cases
(n ¼ 23, 4.8%).
In the binary logistic regression analysis adjusted for age and
sex, the logarithmically transformed sHLA-DR level associated
inversely with ACS (OR ¼ 0.811; 95% CI ¼ 0.681e0.966, p ¼ 0.019).
In the multivariable-adjusted binary logistic regression, the asso-
ciationwas no longer significant (OR¼ 0.938; 95% CI¼ 0.764e1.152,
p ¼ 0.497), indicating that differences in sHLA-DR levels between
cases and controls were not explained by disease status, but by
other factors differing between cases and controls (Table 3). We
Table 1
Baseline characteristics.
Characteristic Cases Controls p-value
n 477 475
Female 167 (35.0) 169 (35.6) 0.854
Age (years) 50.7 ± 7.0 53.0 ± 10.7 <0.001
Age range (years) 26.6e64.7 24.4e71.0
BMI (kg/m2) 28.5 ± 5.7 (n ¼ 472) 27.3 ± 4.6 <0.001
Risk factors
Smoking status
Never-smoker 106 (22.2) 235 (49.5) <0.001
Current smoker 287 (60.2) 109 (22.9) <0.001
Ever-smoker (current þ ex) 371 (77.8) 240 (50.5) <0.001
Diabetic 66 (13.8) 38 (8.0) 0.004
Hypertensive 287 (60.2) 273 (57.5) 0.398
HLA-DRB1*01 positive 169 (35.5) 129 (27.3) 0.007
Comorbidities
Asthma 25 (5.2) 45 (9.5) 0.012
Cancer 11 (2.3) 26 (5.5) 0.011
Rheumatoid arthritis 20 (4.3) 12 (2.5) 0.154
Laboratory parameters
CRP (mg/l) 14.8 ± 27.2 2.5 ± 5.5 <0.001
TLC (10E9/ml), 10.1 ± 4.0 (n ¼ 460) e e
TC (mmol/l) 4.7 ± 1.2 (n ¼ 399) 5.4 ± 0.9 <0.001
HDL-C (mmol/l) 1.2 ± 0.4 (n ¼ 401) 1.4 ± 0.4 <0.001
LDL-C (mmo/l) 2.7 ± 1.0 (n ¼ 371) 3.3 ± 0.8 <0.001
TG (mmol/l) 1.9 ± 1.7 (n ¼ 403) 1.5 ± 0.9 <0.001
TnT (ng/l) 2.7 ± 4.2 (n ¼ 385) e e
Medication
b-blockers 144 (62.3) 77 (16.2) <0.001
ACE inhibitors 69 (37.7) 43 (9.1) <0.001
ATR blockers 42 (25.9) 34 (7.2) <0.001
Diuretic 24 (14.5) 27 (5.7) <0.001
Lipid lowering therapy 129 (60.6) 77 (16.2) <0.001
Data is presented as mean ± SD or number of study subjects (%).
BMI, body mass index; CRP, C-reactive protein; TLC total leukocyte count; TC, total
cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipo-
protein-cholesterol; TG, triglycerides; TnT, troponin T; ACE, angiotensin-converting
enzyme; ATR, angiotensin receptor.
HLA-DRB1*01 positive ¼ 1 or 2 allele copies of HLA-DRB1*01.
Data of BMI, TLC, TC, HDL-C, LDL-C, TG, TnT, b-blockers, ACE inhibitors, ATR blockers,
diuretic and lipid lowering therapy were missing from some of the cases.
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of the models, adjustment for smoking status reduced the associ-
ation between sHLA-DR levels and ACS (Table 3). However, the
interaction term between smoking status and logarithmically
transformed sHLA-DR level was insignificant in relation to ACS
patient status, in the binary logistic regression model using ACS
patient status as a dependent variable, and logarithmically trans-
formed sHLA-DR level, smoking status and interaction term be-
tween smoking status and logarithmically transformed sHLA-DR
level as explanatory variables.Table 2
Soluble HLA-DR serum levels in study subjects.
sHLA-DR serum levels Cases
sHLA-DR level, mean (mg/ml) 1.71 ± 9.53
sHLA-DR level, range (mg/ml) 0.05e161.77
Log-transformed sHLA-DR level, mean (ng/ml) 2.18 ± 0.72
Log-transformed sHLA-DR level, range (ng/ml) 1.70e5.21
sHLA-DR groups, n (%)
<0.100 mg/ml (I) 270 (56.6)
0.100e0.300 mg/ml (II) 92 (19.3)
0.301e2.000 mg/ml (III) 68 (14.3)
>2.000 mg/ml (IV) 47 (9.9)
a Mann-Whitney U test.
b Pearson Chi-square test.
c Mantel-Haenszel Linear-by-Linear Association test for trend.3.3. sHLA-DR levels and cardiovascular risk factors
Next, we sought to assess the correlation of sHLA-DR and car-
diovascular risk factors. In both cases and controls, sHLA-DR levels
correlated inversely with current smoking (rho ¼ -0.112, p ¼ 0.026
and rho ¼ - 0.241, p < 0.0001, respectively). In cases, no other
correlations were found, whereas in controls sHLA-DR levels also
correlated inversely with age (rho ¼ -0.111, p ¼ 0.016) and HLA-
DRB1*01 positivity (rho ¼ -0.110, p ¼ 0.017). The only factor with a
significant positive correlation with sHLA-DR was the history of
rheumatoid arthritis in controls (rho ¼ 0.153, p ¼ 0.001). The
Spearman's rank-order correlations between sHLA-DR levels and
different variables are summarized in Supplementary Table 1.
When the different sHLA-DR groups (I-IV) were compared
against the risk factors, current smoking showed a significant linear
trend with decreasing sHLA-DR levels in both cases and controls
and rheumatoid arthritis showed a linear trend with increasing
sHLA-DR levels in controls (Supplementary Table 2A and B).
We assessed the associations between groups of sHLA-DR level
with cardiovascular risk factors by ordinal logistic regression
analysis adjusted for age and sex. The results showed that current
smoking was inversely associated with sHLA-DR levels in cases and
controls (OR ¼ 0.592; 95% CI ¼ 0.553e0.908; p ¼ 0.016 and
OR¼ 0.356; 95% CI¼ 0.226e0.563; p¼ 0.000010). In addition,HLA-
DRB1*01 positivity was inversely and rheumatoid arthritis directly
associated with sHLA-DR levels in controls (OR ¼ 0.595; 95%
CI ¼ 0.401e0.882; p ¼ 0.010 and OR ¼ 5.865; 95%
CI ¼ 2.042e16.861; p ¼ 0.001). Multivariable ordinal logistic
regression model adjusted for age and sex, including BMI, smoking
status (current versus never-smoking), diabetes, HLA-DRB1*01,
asthma, cancer, rheumatoid arthritis and CRP as explanatory vari-
ables, did not change these results.
Number of cigarettes smoked per day and duration of smoking
cessation data were available only for controls and these data were
not associated with sHLA-DR levels. Table 4 summarizes the dif-
ferences in clinical variables between current smokers and never-
smokers among cases and controls.4. Discussion
In this study, we discovered a previously unreported association
between smoking and lower sHLA-DR levels. This association was
confounding our preliminary observation, which showed that ACS
patients had lower sHLA-DR levels than controls. As the case
population included more smokers than the control population,
after correcting for smoking status, no association between sHLA-
DR levels and ACS patient status could be seen. This finding raises
the question whether possible associations between smoking and
sHLA-DR levels should always be considered when analysing sHLA-Controls p-value p-value for trendc
2.83 ± 17.11 0.032a
0.05e268.43








Binary logistic regression models of the associations between logarithmically transformed sHLA-DR levels and ACS patients.
ACS patient status
p-value OR 95% CI
Lower Upper
Logarithmically transformed sHLA-DR level
Age and sex adjusted 0.019 0.811 0.681 0.966
Age, sex and smoking status adjusted 0.292 0.906 0.755 1.088
Multivariable adjusteda 0.540 0.938 0.764 1.152
Multivariable adjusted without smoking statusb 0.047 0.820 0.673 0.997
ACS, acute coronary syndrome.
OR, odds ratio; CI, confidence interval.
a Adjusted for sex and baseline characters differing between cases and controls: age, BMI, smoking status (never-versus ever-smoker), diabetes, HLA-DRB1*01 carrier status,
cancer, asthma and CRP.
b Adjusted for sex and baseline characters differing between cases and controls: age, BMI, diabetes, HLA-DRB1*01 carrier status, cancer, asthma, and CRP except for smoking
status (never- versus ever-smoker).
Table 4
Differences in clinical parameters between current smokers and never-smokers among cases and controls.
Cases Controls
Current smokers Never-smokers p-valuea Current smokers Never-smokers p-valueb
n 287 106 109 235
Female 87 (30.3) 48 (45.3) 0.006 92 (39.1) 92 (39.1) 0.208
Age in years 49.8 ± 7.1 52.1 ± 6.6 0.009 51.7 ± 9.3 52.4 ± 11.1 0.242
BMI (kg/m2) 28.3 ± 5.5 29.1 ± 5.9 0.305 27.0 ± 4.3 27.0 ± 4.6 0.655
STEMI 147 (51.2) 46 (43.4) 0.169 e e e
NSTEMI 121 (42.2) 49 (46.2) 0.470 e e e
UA 19 (6.6) 11 (10.4) 0.213 e e e
Diabetic 33 (11.5) 20 (18.9) 0.058 8 (7.3) 16 (6.8) 0.857
Hypertensive 165 (57.5) 68 (64.2) 0.233 60 (55.0) 135 (57.4) 0.676
HLA-DRB1*01 positive 97 (33.9) 49 (46.2) 0.025 32 (29.6) 58 (24.8) 0.344
Asthma 14 (4.9) 6 (5.7) 0.754 6 (5.5) 22 (9.4) 0.224
Cancer 5 (1.7) 2 (1.9) 1.000 6 (5.5) 10 (4.3) 0.592
Rheumatoid arthritis 10 (3.5) 9 (8.5) 0.060 2 (1.8) 7 (3.0) 0.725
CRP (mg/l) 13.1 ± 19.6 18.0 ± 33.5 0.490 2.9 ± 5.7 2.6 ± 6.3 0.031
TLC (10E9/ml) 11.1 ± 4.2 9.0 ± 3.3 <0.001 e e
TC (mmol/l) 4.8 ± 1.2 4.7 ± 1.1 0.885 5.5 ± 0.9 5.3 ± 0.9 0.054
HDL-C (mmol/l) 1.2 ± 0.4 1.3 ± 0.4 0.058 1.4 ± 0.4 1.4 ± 0.4 0.922
LDL-C (mmo/l) 2.7 ± 1.0 2.7 ± 1.0 0.992 3.4 ± 0.9 3.3 ± 0.8 0.201
TG (mmol/l) 2.0 ± 2.0 1.7 ± 1.0 0.069 1.6 ± 0.9 1.4 ± 0.8 0.115
TnT (ng/l) 2.8 ± 4.5 2.6 ± 3.4 0.741 e e e
b-blockers 79 (62.7) 32 (58.2) 0.566 19 (17.4) 39 (16.6) 0.847
ACE inhibitors 37 (37.8) 14 (31.1) 0.441 9 (8.3) 22 (9.4) 0.739
ATR blockers 20 (23.5) 10 (24.4) 0.915 7 (6.4) 17 (7.2) 0.783
Diuretic 13 (15.1) 4 (9.5) 0.580 6 (5.5) 12 (5.1) 0.877
Lipid lowering therapy 65 (56) 28 (54.9) 0.892 13 (11.9) 27 (11.5) 0.906
Data is presented as mean ± SD or number of study subjects (%).
BMI, body mass index; STEMI, ST-elevation myocardial infarction; NSTEMI, non ST-elevation myocardial infarction; UA, unstable angina; CRP, C-reactive protein; TLC total
leukocyte count; TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG, triglycerides; TnT, troponin T; ACE,
angiotensin-converting enzyme; ATR, angiotensin receptor.
HLA-DRB1*01 positive ¼ 1 or 2 allele copies of HLA-DRB1*01.
a Current smoking cases versus never-smoking cases.
b Current smoking controls versus never-smoking controls.
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smoking, and when the frequency of smokers differs between the
study groups.4.1. sHLA-DR and smoking
Cigarette smoking has both pro-inflammatory and immune
suppressive influences on the immune system [19]. Smoking in-
creases the risk of various autoimmune diseases with mechanisms
which are still poorly understood [20,21]. It is a strong environ-
mental risk factor for coronary artery disease as well as for rheu-
matoid arthritis [22,23].
To our knowledge, the previous studies of sHLA-DR have not
assessed the associations between smoking and sHLA-DR levels.Interestingly, alveolar macrophages of smokers have been observed
to express less HLA-DR compared to alveolar macrophages of non-
smokers [24,25]. As the surface expression of HLA-DR has been
shown to correlate with sHLA-DR [4], this could corroborate our
findings. As our material seems to be nearly three times larger than
any of the previous studies of sHLA-DR, the previous studies may
also have been underpowered to detect such an association
[1e8,10e12,26e34].
It is important to note that smoking explained only part of the
variation in sHLA-DR levels and the strength of the correlation was
modest. However, in cases, no other factor was identified with a
significant correlationwith sHLA-DR. In the control population, age,
rheumatoid arthritis and HLA-DRB1*01 carrier status were all
associated with sHLA-DR. Even though the amount of smoking per
J. Tolva et al. / Atherosclerosis 266 (2017) 58e6362day did not correlate with sHLA-DR, we think that the association
between smoking and sHLA-DR was the most important associa-
tion as i) it was seen both in case and in control populations ii) in
the control population, smoking showed stronger correlation to
sHLA-DR levels than other variables and iii) adjusting for smoking
diminished the observed association between sHLA-DR levels and
ACS in the binary logistic regression analyses.
4.2. sHLA-DR and inflammation
Previous, smaller studies (ranging from 5 to 386 study subjects)
have shown that sHLA-DR serum or plasma levels are elevated in
patients with HLA class II-associated inflammatory disorders. Even
though the HLA-DRB1*01 was associated with ACS in the present,
largest study of sHLA-DR (958 study subjects), we could not find an
association between ACS and sHLA-DR. However, we were able to
confirm the previously reported association of rheumatoid arthritis
with higher sHLA-DR levels in our control population [8]. Other
markers of inflammation or CRP were not associated with sHLA-DR
levels. In controls, increasing age usually associated with increased
levels of inflammation, exhibited inverse correlationwith sHLA-DR.
In a previous study, sHLA-DR serum levels were higher in
rheumatoid arthritis patients with disease-associated epitope,
including HLA-DRB1*01 and HLA-DRB1*04 alleles, compared to
rheumatoid arthritis patients without this disease-associated
epitope [8]. In the present study, HLA-DRB1*01 negative controls
had higher serum levels of sHLA-DR than HLA-DRB1*01 positive
controls. By contrast, we did not observe any correlation between
HLA-DRB1*01 allele positivity and sHLA-DR serum levels in cases.
On the other hand, HLA-DRB1*01 negative cases were current
smokers with a significantly higher frequency compared to HLA-
DRB1*01 positive cases, which might have affected the results.
We detected sHLA-DR levels0.100 mg/ml and nearly half of our
cases and controls had detectable levels of sHLA-DR in serum. By
contrast in former studies the percentage of control subjects
showing detectable levels of sHLA-DR in serum has ranged from 8
to 100%. This is probably due to different quantification methods
which complicates the comparison of sHLA-DR levels between
different studies. Given the lack of established methods for sHLA-
DR measurement, we performed validations to confirm our
method.
4.3. Limitations
Our study has some limitations that should be considered. We
were able to obtain only one serum sample from each study subject.
Thus, we did not knowwhether the detected sHLA-DR level was the
case's constant state or, for example, a temporary consequence of
ACS. Our control population was also older than the case popula-
tion. In addition, smoking data were self-reported, which made it
possible for study subjects to misreport their smoking habits.
Additionally, we did not have information of amount and duration
of smoking in cases, which could have affected the results. We did
not use statistical adjustments for multiple testing because we
wanted to avoid to increase the probability of considering truly
important associations as insignificant. We rather carefully
described the methods we used and explained the motives we had
behind the different analyses.
4.4. Conclusions
The results indicate for the first time that lower sHLA-DR levels
are associated with smoking, but not independently associated
with ACS. This is an important finding because the previous studies
of sHLA-DR have not accounted for the possible associationsbetween smoking and sHLA-DR levels. Further studies are required
to confirm these novel results and explore the mechanisms behind
the observed associations.
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